16/12/2022
MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), today announces the successful...
We use cookies on the website sunstone.eu in order to generate statistics and to maximize user-friendliness and improve functionality. By using our website, you consent to our use of cookies. Click on cookie settings below if you wish to disable cookies. Or you can read more about what cookies are, how we use them and how you disable cookies Here.
Cookie settingsAccept Privacy & Cookies Policy
Recent Comments